- Home
- IFRX vs PCM Comparison
IFRX vs PCM Comparison
Compare IFRX & PCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IFRX | PCM |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.1M | 82.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | IFRX | PCM |
|---|---|---|
| Price | $1.14 | $6.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 765.5K | 29.1K |
| Earning Date | 11-10-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.68% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $73,729.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,075.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.71 | $6.88 |
| 52 Week High | $2.77 | $10.20 |
Technical Indicators
Market Signals| Indicator | IFRX | PCM |
|---|---|---|
| Relative Strength Index (RSI) | 50.01 | 34.26 |
| Support Level | $0.96 | $6.09 |
| Resistance Level | $1.16 | $6.15 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 88.08 | 4.35 |
Price Performance
Historical ComparisonAbout IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About PCM PCM Fund Inc.
Pcm Fund Inc is a closed-end investment management company. Its investment objective is to seek current income as a primary focus and also capital appreciation. The Fund invests in agency-guaranteed mortgage-backed securities, private-label mortgage-backed securities, high-yield corporate debt securities, and commercial mortgage-backed securities.